Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

La farmacéutica GSK tocó su máximo trimestral en marzo tras la publicación de datos clínicos, nuevos acuerdos y el respaldo ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in the stock before that. The post GSK’s share price looks a steal to me ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

2025 Healthcare & Pharmaceuticalscategory European regulators to review GSK's asthma drug Nucala to treat COPD March 24, 2025 Healthcare & Pharmaceuticalscategory Brazil's Hypera to launch an ...

La FDA autoriza el antibacteriano gepotidacina, primero de clase y primero frente a ITUs en 30 años, mientras que la EMA acepta revisar el uso de mepolizumab para añadirle la EPOC. Los compuestos ...

During an asthma attack, your airways swell, become inflamed, and produce extra mucus. As the muscles around your airways contract, your bronchial tubes narrow. You may cough or wheeze and find it ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Commences up to GBP330 million share buyback programme. Says this represents the remainder of the ...